Drug Approval | March 17, 2022
Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
Since 1993, Beghou Consulting has helped life sciences companies - especially emerging pharmaceutical companies - establish and manage commercial operations to better market and sell therapies
According to the Indian Council of Medical Research (ICMR), there will be an estimated 12 % rise in cancer cases in India in the next five years
The investment will accelerate the overall Sarclisa development program
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
OCE+ uses IQVIA’s industry-leading data and advanced analytics to deliver AI-driven recommendations directly into the daily workflows of life sciences commercial teams
Machine learning approach to systems biology combined with ligand discovery platform
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Empowers the lab to do more in less time within the existing floor plan by integrating clinical chemistry and immunoassay testing onto a single platform
Subscribe To Our Newsletter & Stay Updated
